A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Yabuki, Chiori ^a   Komatsu, Hidetoshi ^a   Tsujihata, Yoshiyuki ^a   Maeda, Risa ^a   Ito, Ryo ^a   Matsuda Nagasumi, Kae ^a   Sakuma, Kensuke ^a   Miyawaki, Kazumasa ^a   Kikuchi, Naoya ^a   Takeuchi, Koji ^a   Habata, Yugo ^a   Mori, Masaaki ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; FASIGLIFAM; FATTY ACID; G PROTEIN COUPLED RECEPTOR 40; GAMMA LINOLENIC ACID; GLUCOSE; INSULIN;

ANIMAL CELL; ARTICLE; BINDING SITE; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; FATTY ACID BLOOD LEVEL; HUMAN; HUMAN CELL; IN VIVO STUDY; INSULIN LIKE ACTIVITY; INSULIN RELEASE; KNOCKOUT MOUSE; LIPOLYSIS; MOUSE; NONHUMAN; PANCREAS ISLET CELL; POINT MUTATION; RAT;

ALLOSTERIC REGULATION; ANIMALS; BENZOFURANS; CELL LINE; CRICETINAE; DIABETES MELLITUS, TYPE 2; DRUG PARTIAL AGONISM; FATTY ACIDS, NONESTERIFIED; GAMMA-LINOLENIC ACID; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MUTATION; RATS; RECEPTORS, G-PROTEIN-COUPLED; SULFONES;

EID: 84885417075     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076280     Document Type: Article

References (43)

1. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, et al. (2003) Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422: 173-176.
2. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, et al. (2003) The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 278: 11303-11311.
3. Nagasumi K, Esaki R, Iwachidow K, Yasuhara Y, Ogi K, et al. (2009) Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 58: 1067-1076.
4. Alquier T, Peyot ML, Latour MG, Kebede M, Sorensen CM, et al. (2009) Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 58: 2607-2615.
5. Matsuda-Nagasumi K, Takami-Esaki R, Iwachidow K, Yasuhara Y, Tanaka H, et al. (2013) Lack of GPR40/FFAR1 does not induce diabetes even under insulin resistance condition. Diabetes Obes Metab 15: 538-545.
6. Edfalk S, Steneberg P, Edlund H, (2008) Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57: 2280-2287.
7. Negoro N, Sasaki S, Mikami S, Ito M, Suzumi M, et al. (2010) Discovery of TAK-875: A potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett 1: 290-294.
8. Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, et al. (2011) TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther 339: 228-237.
9. Fujiwara K, Maekawa F, Yada T, (2005) Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet beta-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release. Am J Physiol Endocrinol Metab 289: E670-677.
10. Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, et al. (2012) The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J Pharmacol Exp Ther 340: 483-489.
11. Briscoe CP, Peat AJ, McKeown SC, Corbett DF, Goetz AS, et al. (2006) Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol 148: 619-628.
12. Christiansen E, Urban C, Merten N, Liebscher K, Karlsen KK, et al. (2008) Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes. J Med Chem 51: 7061-7064.
13. Lin DC, Zhang J, Zhuang R, Li F, Nguyen K, et al. (2011) AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One 6: e27270.
14. Sasaki S, Kitamura S, Negoro N, Suzuki M, Tsujihata Y, et al. (2011) Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists. J Med Chem 54: 1365-1378.
15. Negoro N, Sasaki S, Mikami S, Ito M, Tsujihata Y, et al. (2012) Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent. J Med Chem 55: 3960-3974.
16. Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, et al. (2012) TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379: 1403-1411.
17. Araki T, Hirayama M, Hiroi S, Kaku K, (2012) GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab 14: 271-278.
18. Naik H, Vakilynejad M, Wu J, Viswanathan P, Dote N, et al. (2012) Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: Results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 52: 1007-1016.
19. Kaku K, Araki T, Yoshinaka R, (2012) Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese Patients with inadequately controlled type 2 diabetes. Diabetes Care 36(2): 245-250.
20. Hoyer D, Boddeke HW, (1993) Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol Sci 14: 270-275.
21. Vaag A, Skott P, Damsbo P, Gall MA, Richter EA, et al. (1991) Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 88: 1282-1290.
22. Boden G, Chen X, Ruiz J, White JV, Rossetti L, (1994) Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 93: 2438-2446.
23. Stein DT, Esser V, Stevenson BE, Lane KE, Whiteside JH, et al. (1996) Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J Clin Invest 97: 2728-2735.
24. Dobbins RL, Chester MW, Daniels MB, McGarry JD, Stein DT, (1998) Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes 47: 1613-1618.
25. Haber EP, Ximenes HM, Procopio J, Carvalho CR, Curi R, et al. (2003) Pleiotropic effects of fatty acids on pancreatic beta-cells. J Cell Physiol 194: 1-12.
26. Morgan NG, (2009) Fatty acids and beta-cell toxicity. Curr Opin Clin Nutr Metab Care 12: 117-122.
27. Lan H, Hoos LM, Liu L, Tetzloff G, Hu W, et al. (2008) Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 57: 2999-3006.
28. Tan CP, Feng Y, Zhou YP, Eiermann GJ, Petrov A, et al. (2008) Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 57: 2211-2219.
29. Sum CS, Tikhonova IG, Neumann S, Engel S, Raaka BM, et al. (2007) Identification of residues important for agonist recognition and activation in GPR40. J Biol Chem 282: 29248-29255.
30. Tikhonova IG, Sum CS, Neumann S, Thomas CJ, Raaka BM, et al. (2007) Bidirectional, iterative approach to the structural delineation of the functional "chemoprint" in GPR40 for agonist recognition. J Med Chem 50: 2981-2989.
31. Sum CS, Tikhonova IG, Costanzi S, Gershengorn MC, (2009) Two arginine-glutamate ionic locks near the extracellular surface of FFAR1 gate receptor activation. J Biol Chem 284: 3529-3536.
32. Lu SY, Jiang YJ, Lv J, Wu TX, Yu QS, et al. (2010) Molecular docking and molecular dynamics simulation studies of GPR40 receptor-agonist interactions. J Mol Graph Model 28: 766-774.
33. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD, (1988) Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 37: 1020-1024.
34. Meijssen S, Cabezas MC, Ballieux CG, Derksen RJ, Bilecen S, et al. (2001) Insulin mediated inhibition of hormone sensitive lipase activity in vivo in relation to endogenous catecholamines in healthy subjects. J Clin Endocrinol Metab 86: 4193-4197.
35. Takeuchi M, Hirasawa A, Hara T, Kimura I, Hirano T, et al. (2012) FFA1-selective agonistic activity based on docking simulation using FFA1 and GPR120 homology models. Br J Pharmacol 168(7): 1570-1583.
36. Lin DC, Guo Q, Luo J, Zhang J, Nguyen K, et al. (2012) Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol 82: 843-859.
37. Xiong Y, Swaminath G, Cao Q, Yang L, Guo Q, et al. (2013) Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1. Mol Cell Endocrinol 369(1-2): 119-129.
38. Luo J, Swaminath G, Brown SP, Zhang J, Guo Q, et al. (2012) A Potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS One 7: e46300.
39. Leifke E, Naik H, Wu J, Viswanathan P, Demanno D, et al. (2012) A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther 92: 29-39.
40. Langmead CJ, Christopoulos A, (2006) Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends Pharmacol Sci 27: 475-481.
41. Miyazaki J, Araki K, Yamato E, Ikegami H, Asano T, et al. (1990) Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology 127: 126-132.
42. Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Habata Y, et al. (2000) Identification of neuromedin U as the cognate ligand of the orphan G protein-coupled receptor FM-3. J Biol Chem 275: 21068-21074.
43. Sutton R, Peters M, McShane P, Gray DW, Morris PJ, (1986) Isolation of rat pancreatic islets by ductal injection of collagenase. Transplantation 42: 689-691.